Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2013 | 04:44pm CET
   By Melodie Warner 
 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
11/17 REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentation
11/15 REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentation
11/13 Poor earnings updates keep European shares at seven-week low
11/13 NASDAQ 100 MOVERS : Disca, has
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/13 REGENERON PHARMACEUTICALS : and Sanofi to Present New Analyses from the Praluent..
11/09 REGENERON PHARMACEUTICALS : Dupilumab Significantly Reduced Steroid Use, Asthma ..
11/09 REGENERON PHARMACEUTICALS : to Share Clinical Progress of REGN1979 and Cemiplima..
11/08 REGENERON PHARMACEUTICALS, INC. (NAS : REGN) Files An 8-K Results of Operations ..
11/08 NASDAQ 100 MOVERS : Ctxs, atvi
More news
News from SeekingAlpha
11/16 YOUR DAILY PHARMA SCOOP : A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tu..
11/15 5 Reasons To Buy The Dip - Cramer's Mad Money (11/14/17)
11/14 YOUR DAILY PHARMA SCOOP : Heron Undervalued, Theravance Submits NDA, Nektar Cont..
11/13 YOUR DAILY PHARMA SCOOP : Regeneron's Appeal, Good News For Amgen, Bristol-Myers..
11/13 INVESTOR BIASES : Be Aware To Boost Returns
Financials ($)
Sales 2017 5 765 M
EBIT 2017 2 437 M
Net income 2017 1 451 M
Finance 2017 2 310 M
Yield 2017 -
P/E ratio 2017 31,34
P/E ratio 2018 28,96
EV / Sales 2017 6,90x
EV / Sales 2018 6,10x
Capitalization 42 072 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 474 $
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Charles A. Baker Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS6.67%42 072
GILEAD SCIENCES1.16%94 601
VERTEX PHARMACEUTICALS100.10%37 280
GENMAB3.15%11 878
EXELIXIS, INC.76.93%7 805
BLUEBIRD BIO INC164.51%7 480